Russian Registry of Patients With nAMD
Russian Registry of Patients With Neovascular Age-Related Macular Degeneration (nAMD)
ClinicalTrials.gov Identifier: NCT04935411
Novartis Reference Number: CRTH258ARU01
Last Update: Jul 08, 2021
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Study Description
A three-year, non-randomized, observational, multicenter prospective nAMD study - patient registry.
Interventions
Eligibility Criteria
Inclusion Criteria:
Age > to 18 years
Male or female patients diagnosed with nAMD (with or without previous treatment for nAMD including but not limited to PDT, laser coagulation, vitamins, retinolamine, emoxipine, anti-VEGF therapy or any surgery for nAMD).
Willing and able to provide informed written consent personally or by legal proxy
Exclusion Criteria:
The patient does not meet the inclusion criteria;
The patient is simultaneously participating in a different nAMD therapy study.
Study Locations
Contacts
Have a question?
Call 1-888-669-6682 or email [email protected]